)
)
)
Ed Arce
Managing Director, Senior Biotechnology Analyst
,
WestPark Capital
Ed Arce joined WestPark Capital in July 2025. He was most recently at H.C. Wainwright & Co. where he spent the prior 10 years before joining WestPark Capital. Mr. Arce covers emerging and small-to-midcap (SMID) biotechnology companies, focused on several therapeutic areas including hepatology; cardiovascular, renal & metabolism (CRM); inflammation & immunology (I&I); gastroenterology; and rare diseases. Mr. Arce has nearly 20 years of equity research experience including at Roth Capital Partners, MLV & Co., Wedbush Securities and UBS Securities. In 2017, Mr. Arce was awarded the No. 1 Stock Picker in Biotechnology in the United States by the Thomson Reuters Analyst Awards. Mr. Arce holds a B.S. in Civil Engineering and an MBA from Florida International University, an M.S. in Finance from Boston College, and an Executive Education Certificate from Columbia University by completing the Chief Financial Officer (CFO) Program.
Sessions
-
Derisking Commercialization Plans to Attract Investment03-Mar-2026Pompeii Ballroom
-
Derisking Commercialization Plans to Attract Investment03-Mar-2026Pompeii Ballroom
){kind=logo}
)
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
